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Uterotonic therapy is critical in
modern obstetric care, and we have
made massive progress towards mak-
ing it available to every pregnant
woman around the globe. Supply
routes have been improved, and
alternative packages like Uniject
have been developed to try to make
the logistics of injecting easier. But
Torlini et al. show that the quality of
oxytocin remains a problem in set-
tings where the availability of fridges
is limited and electricity supplies are
patchy. In their review of published
studies, over a third of samples had
inadequate levels of oxytocin and
over 45% failed quality tests.
How big a problem is this? Increas-
ing the availability of oxytocin glob-
ally has been a central plank of safe
motherhood strategy for at least the
last 20 years, over which time mater-
nal deaths have decreased by 45%.
The increase in oxytocin availability
was thought to have played an impor-
tant role in this, but this is very diffi-
cult to quantify. For although
numerous studies have shown that
oxytocin prophylaxis reduces postna-
tal blood loss in women at low risk, it
is questionable as to whether it actu-
ally prevents maternal death (Weeks
et al. BMJ 2015;351:h3251). In set-
tings with minimal health services,
about one in 200 pregnancies will end
in the mother’s death from postpar-
tum haemorrhage (PPH). But most of
these are caused by uterine rupture or
placental pathology (abruption, prae-
via or retained), for which oxytocics
are relatively ineffective. Preventing
maternal deaths from PPH globally
will take more than oxytocin: provid-
ing safe blood transfusion and skilled
surgery are likely to be far more
important. The role of oxytocin in
PPH is likely to be more about reduc-
ing the morbidity of postnatal anae-
mia than reducing maternal deaths.
Unfortunately there are also risks
to intrapartum oxytocin. This is
mainly linked to uterine hyperstimu-
lation when oxytocin is used for
induction and augmentation. But
oxytocin infusions are also associated
with retained placenta in a dose-
dependent fashion: 10 hours of oxy-
tocin increases the risk of retained
placenta by more than six times
(Endler et al. Obstet Gynecol
2012;119:801–9). PPHs are common
after a long augmented labour, but
this may result from prolonged
labour rather than from oxytocin
exposure, as placebo-controlled ran-
domised trials of intrapartum oxy-
tocin use show no increase in PPH.
The dangers multiply in settings
where it is used indiscriminately.
Intrapartum intramuscular oxytocin
has become a common community
treatment for slow labour in some
parts of the world, with reports of
unskilled health workers injecting
oxytocin routinely to speed up labour.
Overall, in these settings, intrapartum
oxytocin infusions seem to double the
number of perinatal deaths (Lovold
et al. Int J Gynaecol Obstet 2008;103:
276–82).
Increasing the quality and availabil-
ity of oxytocin is certainly important
for improving maternity outcomes
worldwide, but only if used in the con-
text of good-quality care. If the issues
of poor quality care are not simultane-
ously addressed, then it could easily
cause more harm than good.
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